Comparison of the new cardioselective beta-blocker nebivolol with bisoprolol in hypertension: the Nebivolol, Bisoprolol Multicenter Study (NEBIS)
I Czuriga, I Riecansky, J Bodnar, T Fulop… - … drugs and therapy, 2003 - Springer
Objective: The aim of the present study was to evaluate the antihypertensive efficacy of the
highly beta 1-selective adrenergic antagonist nebivolol in comparison with bisoprolol in the …
highly beta 1-selective adrenergic antagonist nebivolol in comparison with bisoprolol in the …
Efficacy and tolerability profile of Nebivolol vs Atenolol in mild‐to‐moderate essential hypertension: Results of a double‐blind randomized multicentre trial
G Grassi, FQ Trevano, A Facchini, T Toutouzas… - Blood …, 2003 - Taylor & Francis
The objective of this 12‐week double‐blind randomized multicentre study was to compare
the efficacy and tolerability of nebivolol, a recently developed beta‐blocking agent with …
the efficacy and tolerability of nebivolol, a recently developed beta‐blocking agent with …
A Randomized, Double‐Blind, Placebo‐Controlled Parallel‐Group Study to Assess the Efficacy and Safety of Nebivolol, a Novel β‐Blocker, in Patients With Mild to …
RJ Weiss, MA Weber, AA Carr… - The Journal of Clinical …, 2007 - Wiley Online Library
This double‐blind, multicenter, randomized placebo‐controlled study evaluated the
antihypertensive efficacy and safety of nebivolol, a selective β1‐adrenoreceptor blocker with …
antihypertensive efficacy and safety of nebivolol, a selective β1‐adrenoreceptor blocker with …
Efficacy and tolerability of nebivolol compared with other antihypertensive drugs: a meta-analysis
LM Van Bortel, F Fici, F Mascagni - American Journal of Cardiovascular …, 2008 - Springer
Background and objective Lowering BP to normal levels without quality of life deterioration
is the most important means of reducing cardiovascular risk. Recent studies have …
is the most important means of reducing cardiovascular risk. Recent studies have …
β-blockers in the management of hypertension: focus on nebivolol
D Wojciechowski, V Papademetriou - Expert review of …, 2008 - Taylor & Francis
Hypertension is a major cardiovascular risk factor but most patients remain asymptomatic for
many years. Successful therapy not only needs to be effective, it also needs to be well …
many years. Successful therapy not only needs to be effective, it also needs to be well …
The role of the new β-blockers in treating cardiovascular disease
MA Weber - American journal of hypertension, 2005 - academic.oup.com
The β-adrenergic receptor blockers play an important role in the management of
cardiovascular disease, including hypertension and chronic heart failure. However …
cardiovascular disease, including hypertension and chronic heart failure. However …
Nebivolol: A third-generation β-blocker for hypertension
JWM Cheng - Clinical therapeutics, 2009 - Elsevier
Background: Nebivolol is a third-generation β1-selective β-blocker that is approved for the
treatment of hypertension. Objective: This article reviews the clinical pharmacology of …
treatment of hypertension. Objective: This article reviews the clinical pharmacology of …
Nebivolol in the management of essential hypertension: a review
W McNeely, KL Goa - Drugs, 1999 - Springer
Nebivolol is a lipophilic β 1-blocker. It is devoid of intrinsic sympathomimetic or membrane
stabilising activity but appears to have nitric oxide-mediated vasodilatory effects. Nebivolol is …
stabilising activity but appears to have nitric oxide-mediated vasodilatory effects. Nebivolol is …
Tolerability of nebivolol in head-to-head clinical trials versus other cardioselective β-blockers in the treatment of hypertension: a meta-analysis
E Ambrosioni, C Borghi - High Blood Pressure & Cardiovascular …, 2005 - Springer
Objective: To assess the comparative tolerability of nebivolol and other cardioselective β-
blockers (CSBs) in the treatment of mild-to-moderate hypertension. Data source: Database …
blockers (CSBs) in the treatment of mild-to-moderate hypertension. Data source: Database …
Metabolic effects and safety profile of nebivolol
AC Pessina - Journal of Cardiovascular Pharmacology, 2001 - journals.lww.com
Nebivolol, compared with classical β-blockers, exerts a high selectivity for β-adrenergic
receptors and also reduces peripheral vascular resistance by modulating nitric oxide (NO) …
receptors and also reduces peripheral vascular resistance by modulating nitric oxide (NO) …